Immunovaccine to Present at 7th Annual Biotech Showcase Conference

HALIFAX, NOVA SCOTIA--(Marketwired - Jan. 7, 2015) - Immunovaccine Inc. ("Immunovaccine") (TSX:IMV), a clinical stage vaccine and immunotherapy company, today announced that its chief executive officer, Marc Mansour, Ph.D., will present a corporate update at the 7^th Annual Biotech Showcase Conference. The conference will take place January 12-14, 2015 at the Parc 55 Wyndham San Francisco Union Square Hotel.

Dr. Mansour's presentation will focus on the latest developments for the Company's pipeline of novel vaccine candidates, including lead cancer vaccine, DPX-Survivac, as well as programs focused on respiratory syncytial virus (RSV), anthrax and Ebola virus. Each of these vaccine candidates is formulated in the Company's proprietary DepoVax™ vaccine adjuvanting delivery platform.

Details of Dr. Mansour's presentation are as follows:

Date: Wednesday, January 14, 2015

Time: 9:30 a.m. (Pacific)

Location: Track C - Mission II Presentation Room (4th Floor)

A live audio webcast of the presentation will be available at the following link: http://edge.media-server.com/m/p/uc7qru8m, as well as on the Company's website at www.imvaccine.com. A webcast replay will be available approximately two hours after the presentation ends and will be accessible for a limited time.

About DepoVax™

DepoVax™ is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the potential for single-dose effectiveness. The DepoVax™ platform is flexible and can be used with a broad range of target antigens for preventative or therapeutic applications. The technology is designed to be commercially scalable, with the potential for years of shelf life stability.

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer), with Immunovaccine also exploring additional studies in other indications including lymphoma and recurrent ovarian cancer. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), anthrax and Ebola virus.

Connect at www.imvaccine.com

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.